Community-acquired Pneumonia Due to Chlamydia Pneumoniae (NCT07679789) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Community-acquired Pneumonia Due to Chlamydia Pneumoniae
France200 participantsStarted 2026-06
Plain-language summary
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.
The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.
The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.
Secondary objectives include;
1. Outpatient management
2. Hospitalization in a medical ward
3. Admission to the intensive care unit
4. In-hospital mortality
5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae
6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
* Availability of clinical data allowing confirmation of pneumonia diagnosis.
Exclusion Criteria:
* Patient opposition to the use of medical data for research purposes.
* Absence of pneumonia diagnosis.
* Insufficient clinical data for analysis.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR
Timeframe: January 2015 to December 2025
Trial details
NCT IDNCT07679789
SponsorCentre Hospitalier de Saint-Denis
Sponsor typeOTHER
Study typeOBSERVATIONAL
Primary completion2026-09
Contact for this trial
Yacine Tandjaoui-Lambiotte, Principal Investigator